Magenta Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019

From Startup Magenta Therapeutics

Link to Full Article: https://investor.magentatx.com/news-releases/news-release-details/magenta-therapeutics-present-37th-annual-jp-morgan-healthcare

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 2, 2019–
Magenta
Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company
developing novel medicines to bring the curative power of bone marrow
transplant to more patients, today announced that the company is
scheduled to present and subsequently participate in a Q&A session at
the 37th Annual J.P. Morgan Healthcare Conference in San
Francisco on Wednesday, January 9, 2019 at 9:30 a.m. PT (12:30 p.m. ET).

A live webcast of the presentation and Q&A session can be accessed under
the “Events & Presentations” page within the Investors & Media section
of the Magenta Therapeutics website at https://investor.magentatx.com/events-and-presentations.
A replay of the webcast will be available on the Magenta Therapeutics
website for 90 days following the event.

About Magenta Therapeutics

Headquartered in Cambridge, Mass., Magenta Therapeutics is a
clinical-stage biotechnology company developing novel medicines for
patients with autoimmune diseases, blood cancers and genetic diseases.
By creating a platform focused on critical areas of unmet need, Magenta
Therapeutics is pioneering an integrated approach to allow more patients
to receive one-time, curative therapies by making the process more
effective, safer and easier.

Forward-Looking Statement

This press release may contain forward-looking statements, including
express or implied statements regarding Magenta’s future expectations,
plans and prospects, including projections regarding future revenues and
financing performance, our long-term growth, the anticipated timing of
our clinical trials and regulatory filings, the development of our
product candidates and advancement of our preclinical programs, as well
as other statements containing the words “anticipate,” “believe,”
“continue,” “could,” “estimate,” “expect,” “intend,” “may,” might,”
“plan,” “potential,” “project,” “should,” target,” “will” or “would” and
similar expressions that constitute forward-looking statements under the
Private Securities Litigation Reform Act of 1995. Although Magenta’s
forward-looking statements reflect the good faith judgment of its
management, these statements are based only on facts and factors
currently known by Magenta. As a result, you are cautioned not to rely
on these forward-looking statements. These and other risks concerning
Magenta’s programs and operations are described in additional detail in
its registration statement on Form S-1, its Quarterly Report on Form
10-Q and its other filings made with the Securities and Exchange
Commission from time to time. Any forward-looking statement made in this
press release speaks only as of the date on which it is made. Magenta
undertakes no obligation to publicly update or revise any
forward-looking statement, whether as a result of new information,
future developments or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190102005142/en/
Source: Magenta Therapeutics

Magenta Therapeutics:Manisha Pai, Vice President,
Communications & Investor Relations617-510-9193mpai@magentatx.com

Please visit their site for more information: Magenta Therapeutics.com

All,Biotechnology,Healthcare News,Startup News
2019-01-02 20:03:47